COPENHAGEN, Denmark, November 9, 2017 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that dosing has commenced in the Phase 2 extension study of MVA-BN® RSV, a universal vaccine candidate designed to elicit a broad antibody and T-cell response against multiple respiratory syncytial virus (RSV) antigens. This study is designed to help determine whether a single shot administration of vaccine is required annually, or if it remains effective over multiple seasons.